Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Fatty's Donut Shop -- Ignore unavailable to you. Want to Upgrade?

To: SteelerStu who wrote (696)	4/17/1999 1:44:00 AM
From: Michael E. Baldino	Read Replies (2) \| Respond to of 5041

*WASP* Some Details here!!! I had e-mailed this stock pick to Fatt Matt for his opinion, and he not only likes it, But asked me to come to the thread to talk about it. While I do not post here often, I am a subscriber to the newsletter and a favorable opinion from FM tells me we have a good one. Before I say more, here are 2 recent news releases that I would like you to read. I always prefer links so that you can see for yourself. But I will cut and paste to save you the trip. FROM YAHOO: (not the threads) biz.yahoo.com Monday April 12, 12:38 pm Eastern Time Company Press Release Cystic Acne Study Brings Dramatic Results MIDVALE, Utah--(BUISNESS WIRE)--April 12, 1999 --Wasatch Pharmaceutical Inc. (OTC BB:WASP - news) has previously announced clinical trials, and the treatment of acne patients in a clinical setting under the direction and cooperation of a major pharmaceutical research entity, and approximately 250 physicians. With several thousand patients having been treated, Wasatch has announced a success rate of 95% with virtually no side effects. Success is interpreted as total or near total eradication of both cystic acne and the less serious grades of acne. This product is used topically, and is far superior to anything now being used by prescription or in the over-the-counter market. With the success of this therapy, entry into the retail market has been solicited by an independent distributor representing eighteen hundred pharmacies. In addition, two major retail chains representing over 30% of the over-the-counter market are accessible through relationships presently representing Wasatch Pharmaceutical. The acne market is a $3 Billion market and with a superior product, Wasatch will aggressively penetrate and control a significant share of this market. This press release contains forward-looking statements regarding Wasatch Pharmaceutical Inc. and its future sales-related activities. Actual results could differ materially from those described or implied in this press release as a result of a number of factors. These include, but are not limited to, the future growth of these markets, any adverse actions by the company's partners, competitive products, other economic factors affecting the company*s markets, the degree of acceptance that new products achieve, and seasonal changes. Readers are referred to public documents filed by Wasatch Pharmaceutical, Inc. with the Securities and Exchange Commission which identify important risk factors that could cause actual results to differ from those contained in any forward-looking statements. Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709 (disclaimer at bottom deleted / same as above) Thursday April 15, 7:30 am Eastern Time Company Press Release Major Funding MIDVALE, Utah--(BUSINESS WIRE)--April 15, 1999 --Wasatch Pharmaceutical Inc. (OTC BB:WASP - news) is now receiving long term funding and will receive up to $25 million over the next twelve months. This funding will be accomplished through a private placement with institutional buyers who will be long term holders of Wasatch Pharmaceutical Inc. stock. Because the Company is now receiving major funding, there will be announcements over the next few weeks concerning activities within Wasatch that will be of great importance to existing and future stockholders of Wasatch. Therefore, it is important that stockholders be diligent in tracking these news releases through the Internet or with their brokers. SI THREAD HEADER: Started By: FJ MANN Date: Apr 13 1999 1:47AM ET This company looks interesting.Looking for more information. Posted on Raging Bull. From investor package. You can call Gary Heist 810-272-1709 CEO Issued and outstanding approximately 15 million. On the float approximately 3.5 million. 1985 clinical tests were conducted and funded by Chesebrough-Ponds, INC a major skin care products company. This was the start of new acne drug. Company has other drugs in the pipeline, to do with eczema, acne and psoriasis. Thats all I have for now I WELCOME ALL NEW FINDINGS AND INFO!!!!!!!!